Abstract
Von Willebrand factor (vWF) is a glycoprotein that plays a major role in normal hemostasis, by functioning as carrier protein for coagulation factor VIII and by mediating platelet adhesion to endothelial lesions. Mutations in the vWF gene result in quantitative and qualitative defects, characteristic for hereditary von Willebrand disease (vWD), the most common inherited coagulation disorder. Quantitative, qualitative or functional, nonhereditary alterations of vWF can also occur later in life, as acquired vWD [1] [2] [3] [4] [5] [6] [7] [8] .
Acquired von Willebrand disease (AvWD) represents a rare and most likely underdiagnosed (or misdiagnosed) category of hemorrhagic syndromes associated to a variety of underlying diseases. It is diagnosed mainly in adults, without any personal or familial history of bleeding. Clinical and laboratory manifestations are similar to those found in the congenital form [1] [2] [3] [4] . Based on the several hundreds of cases reported in literature, the prevalence is evaluated at 0.04%, probably highly underestimated [6] [7] [8] [9] [10] [11] .
The etiology of AvWD is heterogeneous including neoplasia, autoimmune disorders, cardiovascular diseases, therapeutic agents as well as a multitude of other conditions [1, 2, 4, 5, 7, 8, [12] [13] [14] [15] [16] . Table 1 resumes the causes of AvWD. The pathophysiology of AvWD is complex and not yet entirely understood. There are various proposed mechanisms for AvWD in different underlying diseases. Also for one given etiology more than one mechanism could lead to the bleeding condition. The vWF synthesis is decreased only in a minority of AvWD casesmainly those associated with hypothyroidism. In the majority of cases vWD synthesis in megakaryocytes and endothelial cells is normal or even increased, but there is an accelerated vWF clearance from patients' plasma [1, 2, 4, 5, 7, 8, 17] . The increased vWD clearance is mediated by a variety of mechanisms: Table 2 summarizes the mechanisms involved in AvWD.
The most important clinical sign is cutaneous and/or mucosal hemorrhage, same as for constitutional vWD: spontaneous ecchymosis, epistaxis, gum bleeding, gastrointestinal bleeding, hematuria, etc. Nonetheless, the AvWD diagnosis needs high clinical awareness when consulting adult patients with such hemorrhagic manifestations appearing late in life, in the absence of personal or familial antecedents for coagulation disorders. The role of a careful discussion with patients in order to evaluate bleeding history has to be underlined. A watchful evaluation is needed to identify underlying conditions potentially associated with AvWD [1] [2] [3] [4] [5] 7, 8] .
The diagnosis is confirmed through laboratory work-up, demonstrating quantitative or functional vWF anomalies, thus permitting to unveil the pathogenic mechanism [1-5,7,8 19,21-23] .
• 9 /L) counts. Coagulation evaluation was normal, but bleeding time was prolonged (6 min), vWF:Ag was decreased (40%) and ristocetin induced platelet aggregation was altered (810 AU*min; normal range 980-1180 AU*min). Further evaluation showed increased thyroid stimulating hormone (TSH) (6.2µU/mL; normal range 0.6-4.6 µU/mL) plasma levels, low thyroxine (T4) (3.9 µg/dL; normal range 5.13-14.1 µg/dL) levels and the absence of anti-thyroid peroxidase antibodies (ATPO), thus demonstrating hypothyroidism as the AvWD cause. The patient received treatment with thyroxin leading to a resolution of all hemorrhagic manifestations.
Clinical case 2 -Aortic stenosis associated AvWD
A 48 years old man diagnosed in 2013 with moderate aortic stenosis was investigated earlier this year for the spontaneous painful tumefaction of both knees. All tests for inflammatory and immune diseases were negative so an articular punction was performed, showing hemarthrosis. At the same time, cardiologic reevaluation showed progression of the aortic stenosis. Clinical examination on admission in our service showed mild knee tumefaction and pain without other bleedings. Anamnesis revealed no history of personal or familial hemorrhagic events. Blood count, coagulation tests, bleeding time, coagulation factor levels and vWF:Ag were within normal range. Platelet aggregation studies showed normal response to stimulation with ADP, arachidonic acid and collagen, but decreased platelet aggregation after induction with ristocetin (610 AU* min; normal range 980-1180 AU*min) ( Figure 1) ; VvWF:RCo was decreased (38%), as was vWF:RCo/Ag (0.4). The patient was referred to a cardiac surgery service to be evaluated for corrective surgery.
Clinical case 3 -Chronic myeloid leukemia associated AvWD
A 55 years old woman was admitted to our Department for leukocytosis. Her medical history revealed arterial hypertension, progressive fatigue over the past 5 months and recent occur- rence of spontaneous ecchymoses and subcutaneous hematomas. Clinical examination showed several ecchymoses on the upper and lower limbs and splenomegaly (8 cm below costal margin). Blood count showed moderate anemia (Hb=9.8 g/dl), marked leukocytosis (428 x 10 9 /L), normal platelet level (256 x 10 9 /L), a differential count with leftward shift and basophilia (12% blasts, 12% promyelocytes, 14% myelocytes, 14% metamyelocytes, 40% neutrophils, 3% basophils, 3% eosinophils, 1% lymphocytes, 1% monocytes). Routine coagulation (APTT, PT, INR, Fbg) tests were normal. Molecular biology testing showed the presence of the BCR/ABL mutation confirming the diagnosis of chronic myeloid leukemia, accelerated phase. She received cytoreductive treatment with hydroxiureea. During the third day after admission the patient complained of a lumbar pain that referred towards the left thigh and was associated with an antalgic position of the left lower limb (flexion and internal rotation). The pain was associated with extensive subcutaneous hemorrhagic suffusions of the abdominal wall and an abrupt drop in Hb level to 6.2 g/dl. Ultrasonographic and MRI examinations showed a massive hematoma (13/10/6,5 cm) in the left ileo-psoas muscle with extension into the depth of the abdominal wall. The patient received substitution with packed red cells, fresh frozen plasma and cryoprecipitate. Reevaluation of coagulation showed repeatedly normal routine tests along with normal coagulation factors plasma levels. Further evaluation showed normal vWF:Ag -119% but with severe a decrease in platelet aggregation after stimulation with ristocetin (594 AU*min) (Figure 1) , vWF:RCo (19%) and vWF:RCo/Ag (0.16). The treatment was completed with desmopressin and FVIII/vWF concentrate. After 2 days of substitution therapy and cytoreduction combined treatment we noted the amelioration of pain and abdominal wall hematoma, in parallel with a Hb increase and a white blood cell count decrease (65 x 10 9 /L). Reevaluation of hemostasis showed the increase of vWF:Ag to 150% and an improvement in platelet aggregation after stimulation with ristocetin (918 AU*min) (Figure 1 ). Imagistic reevaluation showed substantial reduction of the ileo-psoas hematoma (7/4/2 cm). The patient was released from our Department with the recommendation to start tyrosine kinase inhibitor therapy and a weekly follow-up. Figure 1 shows the graphical representation of results of ristocetin induced platelet aggregation assays performed in cases 2 and 3.
Discussions
Case 1. In patients with hypothyroidism, AvWD is considered the main etiology of hemorrhage. Manfredi et al. published a systematic review including epidemiologic studies and 47 case reports in which diagnostic tests were available as follows: vWF:Ag in 23 cases, vWF activity in 24 cases and FVIII activity in 16 cases. [24] . A recent study performed by Stuijver et al. on 90 patients with overt hypothyroidism at diagnosis showed a mild vWF:Ag and/or vWF:RCo decrease (range 30 -50%) in 33% of cases, corelated with the severity of bleeding and levels of free T4. Patients responded to thyroid replacement treatment [25] .
In our case, bleeding was associated with clinical and laboratory signs of hypothyroidism. The diagnosis of AvWD was established by demonstrating the decline in vWF synthesis (low vWF:Ag) and moderate impairement of vWF function (ristocetin induced platelet agregation) but in the absence of the vWF:RCo assay. The patient had a very good response to thyroxine therapy. Case 2. The subject of cardiovascular disease-associated AvWD is actual. In the report published in 2000 by the International Society of Thrombosis and Hemostasis (ISTH) 21% of 300 AvWD cases were associated with cardio-AvWD is probably highly underdiagnosed or misdiagnosed. The first step towards a correct diagnosis is the awareness of physicians in front of patients with AvWD-associated diseases presenting unusual bleeding. Treatment of the underlying disease (when possible) allows in most cases the control of hemorrhage. These are the reasons why all AvWD cases should be reported in order to gain experience in this rare disease, permitting the improvement of diagnostic and therapeutic skills.
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There is no conflict of interest between authors in this study. The manuscript has been read and approved by all the authors, and each author believes the manuscript represents honest work. vascular disorders. In recent studies the frequency of cardiovascular associated AvWD rises to 40-46% reflecting higher awareness among physicians. In selected patient groups AvWD has been diagnosed in 79% of patients with aortic stenosis [5, 6, 10] . In the vast majority of cases there is a loss of large vWF multimers and decreased vWF:CB/vWF:Ag besides vWF:RCo/ vWF:Ag ratios. The incidence and severity of hemorrhage was correlated with a higher transvalvular gradient and the degree of multimers loss. Cardiac corrective surgery is followed by a rapid improvement of vWF abnormalities [21] . In the reported case the diagnosis was confirmed by decreased ristocetin induced platelet aggregation, vWF:RCo and vWF:RCo/vWF:Ag ratio in the presence of normal vWF:Ag levels. Articular bleeding occurred 2 years after the diagnosis, in association with an aggravation of the aortic stenosis, thus illustrating the correlation between a higher valvular gradient and the severity of coagulation anomalies leading to a clinically significant hemorrhage. Case 3. CML associated AvWD is less frequently reported. In most myeloproliferations occurrence of AvWD is related to high platelet counts. Clinical manifestations usually consist in moderate muco-cutaneous hemorrhage. [1, 2, 4, 7, 8, 12, 13, [18] [19] [20] . Our patient had normal platelet count but associated marked leukocytosis. The hemorrhagic syndrome was severe with massive intramuscular hematoma and secondary anemia. The major bleeding was controlled only after substitution therapy and cytoreduction.
Conclusions
Acquired von Willebrand disease is a rare but potentially severe, even fatal, hemorrhagic disorder associated to a multitude of underlying disorders. Because of its reduced incidence and the necessity of an experienced laboratory,
